These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 23528167

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
    Dou QP, Zonder JA.
    Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
    [Abstract] [Full Text] [Related]

  • 3. The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
    Orlowski RZ.
    Oncology (Williston Park); 2011 Nov 15; 25 Suppl 2(12 0 2):56-64. PubMed ID: 25188482
    [Abstract] [Full Text] [Related]

  • 4. Proteasome inhibitor therapy in multiple myeloma.
    Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC.
    Mol Cancer Ther; 2005 Apr 15; 4(4):686-92. PubMed ID: 15827343
    [Abstract] [Full Text] [Related]

  • 5. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V, Jacobs BS, Hussein MA.
    Drugs R D; 2007 Apr 15; 8(1):1-12. PubMed ID: 17249845
    [Abstract] [Full Text] [Related]

  • 6. An analysis of the safety profile of proteasome inhibitors for treating various cancers.
    Wang H, Guan F, Chen D, Dou QP, Yang H.
    Expert Opin Drug Saf; 2014 Aug 15; 13(8):1043-54. PubMed ID: 25005844
    [Abstract] [Full Text] [Related]

  • 7. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
    Ling SC, Lau EK, Al-Shabeeb A, Nikolic A, Catalano A, Iland H, Horvath N, Ho PJ, Harrison S, Fleming S, Joshua DE, Allen JD.
    Haematologica; 2012 Jan 15; 97(1):64-72. PubMed ID: 21993678
    [Abstract] [Full Text] [Related]

  • 8. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B, Li J, Mao X.
    Curr Pharm Des; 2013 Jan 15; 19(18):3190-200. PubMed ID: 23151134
    [Abstract] [Full Text] [Related]

  • 9. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L, Musolino C.
    Leuk Res; 2014 Jan 15; 38(1):1-9. PubMed ID: 24239172
    [Abstract] [Full Text] [Related]

  • 10. Proteasome inhibitors in the treatment of multiple myeloma.
    McBride A, Ryan PY.
    Expert Rev Anticancer Ther; 2013 Mar 15; 13(3):339-58. PubMed ID: 23477520
    [Abstract] [Full Text] [Related]

  • 11. Role of carfilzomib in the treatment of multiple myeloma.
    Khan RZ, Badros A.
    Expert Rev Hematol; 2012 Aug 15; 5(4):361-72. PubMed ID: 22992230
    [Abstract] [Full Text] [Related]

  • 12. [Proteasome inhibitor].
    Yagi H.
    Nihon Rinsho; 2014 Jun 15; 72(6):1125-9. PubMed ID: 25016815
    [Abstract] [Full Text] [Related]

  • 13. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK, Li M, Tea MN, Pitman MR, Toubia J, Wang PP, Anderson D, Creek DJ, Orlowski RZ, Gliddon BL, Powell JA, Wallington-Beddoe CT, Pitson SM.
    Neoplasia; 2022 Jan 15; 24(1):1-11. PubMed ID: 34826777
    [Abstract] [Full Text] [Related]

  • 14. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
    Bringhen S, Gay F, Donato F, Troia R, Mina R, Palumbo A.
    Expert Opin Investig Drugs; 2014 Sep 15; 23(9):1193-209. PubMed ID: 24905450
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proteasome inhibitor drugs on the rise.
    Joazeiro CA, Anderson KC, Hunter T.
    Cancer Res; 2006 Aug 15; 66(16):7840-2. PubMed ID: 16861477
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.